Stifel lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $7.50 from $9 and keeps a Buy rating on the shares. The firm updated the company’s model post the earnings report and corporate update. The reduced target reflects revised financing assumptions, including the impact of X4’s October financing, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR: